U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07455617) titled 'Study of ABO2102 in KRAS-Mutated Solid Tumors' on Feb. 25.
Brief Summary: This is a multicenter, open-label Phase 1 clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, as well as preliminary anti-tumor activity of ABO2102 as monotherapy and in combination among participants with solid tumors with KRAS mutations.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced / Metastatic Solid Tumor
Intervention:
DRUG: ABO2102 Injection
mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
DRUG: Sintilimab injection
An...